Australian biotechnology industry association AusBiotech has released a series of case studies that represent successful partnerships and investments in the Australian life sciences. AdAlta’s lead program, AD-214, has been featured in the case study released June 2019 called Scarred for Life.
The case study introduces fibrosis, specifically Idiopathic Pulmonary Fibrosis, the indication AD-214 is looking to target, and profiles AdAlta and Pharmaxis who are both companies “working towards re-designing the landscape of fibrosis treatment”.
The full case study can be viewed below and downloaded here. Additional information about AdAlta’s lead candidate, AD-214, being developed to treat Idiopathic Pulmonary Fibrosis can be viewed here.
Ausbiotech Fibrosis case study June 2019